Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2021 Jan;100(1):297-302.
doi: 10.1007/s00277-020-04302-0.

Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

Martin Kaiser  1   2 , Meral Beksaç  3 , Nina Gulbrandsen  4 , Fredrik Schjesvold  4 , Roman Hájek  5 , Philippe Moreau  6 , Felipe de Arriba de la Fuente  7 , María-Victoria Mateos  8 , Sharon West  9 , Andrew Spencer  10 , S Vincent Rajkumar  11 , Kaveri Suryanarayan  12 , Michael Czorniak  12 , Cong Li  12 , Zhaoyang Teng  12 , Richard Labotka  12 , Meletios A Dimopoulos  13
Affiliations
Published Erratum

Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

Martin Kaiser et al. Ann Hematol. 2021 Jan.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
CONSORT diagram. Reproduced with permission from Dimopoulos MA, Gay F, Schjesvold F et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2019;393:253–264
Fig. 2
Fig. 2
Cumulative incidence of new-onset thrombocytopenia (a) and median platelet counts (b) over time in the ixazomib and placebo groups, and actions taken for events of thrombocytopenia (c). Note: More than one action could be taken for a single event of thrombocytopenia
Fig. 3
Fig. 3
Incidence rate by cycle (a) and cumulative incidence (b) of new-onset nausea. Only one patient in the ixazomib arm (< 1%) and no patients in the placebo arm had grade ≥3 nausea. Incidence rate is the number of events in a cycle divided by the sum of patient cycles at risk in a cycle. A patient with an ongoing AE could not be at risk of getting the same AE until it was resolved
Fig. 4
Fig. 4
Incidence rate by cycle (a) and cumulative incidence (b) of new-onset vomiting. No patients in the placebo arm had grade ≥ 3 vomiting. Incidence rate is the number of events in a cycle divided by the sum of patient cycles at risk in a cycle. A patient with an ongoing AE could not be at risk of getting the same AE until it was resolved
Fig. 5
Fig. 5
Incidence rate by cycle (a) and cumulative incidence (b) of new-onset diarrhea. Incidence rate is the number of events in a cycle divided by the sum of patient cycles at risk in a cycle. A patient with an ongoing AE could not be at risk of getting the same AE until it was resolved
Fig. 6
Fig. 6
Cumulative incidence of new-onset PN. Only one patient in the ixazomib arm had grade 3 PN (< 1%), and no patients in either arm had grade 4 PN
See this image and copyright information in PMC

Erratum for

Publication types

LinkOut - more resources